keyword
MENU ▼
Read by QxMD icon Read
search

EULAR

keyword
https://www.readbyqxmd.com/read/28223263/apps-for-people-with-rheumatoid-arthritis-to-monitor-their-disease-activity-a-review-of-apps-for-best-practice-and-quality
#1
Rebecca Grainger, Hermaleigh Townsley, Bonnie White, Tobias Langlotz, William J Taylor
BACKGROUND: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis requiring long-term treatment with regular monitoring by a rheumatologist to achieve good health outcomes. Since people with RA may wish to monitor their own disease activity with a smartphone app, it is important to understand the functions and quality of apps for this purpose. OBJECTIVE: The aim of our study was to assess the features and quality of apps to assist people to monitor their RA disease activity by (1) summarizing the available apps, particularly the instruments used for measurement of RA disease activity; (2) comparing the app features with American College of Rheumatology and European League against Rheumatism (ACR and EULAR) guidelines for monitoring of RA disease activity; and (3) rating app quality with the Mobile App Rating Scale (MARS)...
February 21, 2017: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/28216195/golimumab-in-real-life-settings-2-years-drug-survival-and-predictors-of-clinical-outcomes-in-rheumatoid-arthritis-spondyloarthritis-and-psoriatic-arthritis
#2
Florenzo Iannone, Leonardo Santo, Maria Grazia Anelli, Romano Bucci, Angelo Semeraro, Laura Quarta, Francesca D'Onofrio, Antonio Marsico, Giorgio Carlino, Oriana Casilli, Fabio Cacciapaglia, Carmelo Zuccaro, Paola Chiara Falappone, Francesco Paolo Cantatore, Maurizio Muratore, Giovanni Lapadula
OBJECTIVES: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Drug retention was analyzed using Kaplan-Meier and Cox models...
January 18, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28210632/increased-interleukin-17f-is-associated-with-elevated-autoantibody-levels-and-more-clinically-relevant-than-interleukin-17a-in-primary-sj%C3%A3-gren-s-syndrome
#3
Yuzhou Gan, Xiaozhen Zhao, Jing He, Xu Liu, Yun Li, Xiaolin Sun, Zhanguo Li
Th17 related immune response is pathogenic in primary Sjögren's syndrome (pSS). However, the role of IL-17F, one potent inflammatory member of IL-17 family cytokines in pSS, has not been specifically defined. We recruited one hundred and nine pSS patients and forty-two healthy controls and their serum levels of IL-17A and IL-17F were determined by multiplex cytokine assays. White blood cell, red blood cell, neutrophil, lymphocyte, IgM, IgG, C3, C4, RF, ANA, anti-SSA antibody, and anti-SSB antibody were measured by standard laboratory techniques...
2017: Journal of Immunology Research
https://www.readbyqxmd.com/read/28191456/the-short-form-score-for-the-assessment-and-quantification-of-chronic-rheumatic-affections-of-the-hands-in-daily-clinical-routines-its-sensitivity-to-change-and-preliminary-patient-relevant-variation-values-a-pilot-study
#4
Ulrike Stummer, Bernhard Rintelen, Burkhard F Leeb
OBJECTIVE: The SF-SACRAH was developed to assess the involvement of the hand in rheumatoid arthritis (RA) and hand osteoarthritis (HOA) patients in daily clinical routines. In this pilot study, its sensitivity to change will be assessed longitudinally, and preliminary thresholds for patient relevant changes are derived. METHODS: Ninety-nine outpatients suffering from HOA (n = 55) or RA (n = 44) completed the SF-SACRAH once initially. After approximately 3 months, patients repeated the SF-SACRAH...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28183330/th17-and-cd24-hi-cd27-regulatory-b-lymphocytes-are-biomarkers-of-response-to-biologics-in-rheumatoid-arthritis
#5
Sarah Salomon, Caroline Guignant, Pierre Morel, Gauthier Flahaut, Clément Brault, Clément Gourguechon, Patrice Fardellone, Jean-Pierre Marolleau, Brigitte Gubler, Vincent Goëb
BACKGROUND: The aim was to describe the regulatory B and T cells (Breg and Treg) and T helper 17 (Th17) lymphocytes before and under treatment with biologic drugs, and to assess their potential predictive value as biomarkers of response in rheumatoid arthritis (RA). METHODS: This was a non-randomised, single-centre, prospective study. Patients with active RA (American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) 2010) who required the initiation or switch to any biologic drug except rituximab were included...
February 10, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28176966/efficacy-and-safety-of-non-pharmacological-and-non-biological-pharmacological-treatment-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#6
COMMENT
Andrea Regel, Alexandre Sepriano, Xenofon Baraliakos, Désirée van der Heijde, Jürgen Braun, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
To assess the efficacy and safety of non-biological therapies in patients with axial spondyloarthritis (axSpA) to inform the update of the Assessment of SpondyloArthritis international Society (ASAS)/European League Against Rheumatism (EULAR) recommendations for the management of axSpA. A systematic literature review (2009-2016) of all non-pharmacological treatments, non-biological drugs (except targeted synthetic disease-modifying antirheumatic drugs (DMARDs)) and surgical therapies was performed. Randomised controlled trials (RCTs) and clinical controlled trials were assessed for efficacy and safety, while observational studies with a comparator were assessed for safety...
2017: RMD Open
https://www.readbyqxmd.com/read/28176964/efficacy-and-safety-of-biological-and-targeted-synthetic-dmards-a-systematic-literature-review-informing-the-2016-update-of-the-asas-eular-recommendations-for-the-management-of-axial-spondyloarthritis
#7
Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch, Louise Falzon, Sofia Ramiro
OBJECTIVES: To update the evidence for the efficacy and safety of (b)biological and (ts)targeted-synthetic disease-modifying anti-rheumatic drugs (DMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2016 update of the Assessment of SpondyloArthritis international Society/European League Against Rheumatism (ASAS/EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2009-2016) for randomised controlled trials (RCT), including long-term extensions, strategy trials and observational studies (the latter was only for safety assessment and a comparator was required)...
2017: RMD Open
https://www.readbyqxmd.com/read/28161110/-discontinuation-or-tapering-strategies-of-biologics-in-rheumatoid-arthritis-in-remission
#8
A Mallick, B Fautrel, F Sagez, C Sordet, R-M Javier, H Petit, E Chatelus, N Rahal, J-E Gottenberg, J Sibilia
The arrival of new drugs and new therapeutic strategies allowed to reach sustained remission in an increasing number of patients with rheumatoid arthritis. The study of biologic disease-modifying anti-rheumatic drugs (bDMARDs) adaptation strategies is a need to optimize the benefit/risk balance and cost/effectiveness ratio of these molecules. Current recommendations such as EULAR 2016 propose tapering bDMARDs, especially when combined with a csDMARD, when the patient is in remission after stopping persistent glucocorticoids...
February 1, 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/28155923/diagnosis-prognosis-and-classification-of-early-arthritis-results-of-a-systematic-review-informing-the-2016-update-of-the-eular-recommendations-for-the-management-of-early-arthritis
#9
COMMENT
Charlotte Hua, Claire I Daien, Bernard Combe, Robert Landewe
OBJECTIVE: To update the evidence pertaining to the diagnosis, prognosis and classification of patients with early arthritis (EA), and to inform the 2016 European League Against Rheumatism (EULAR) recommendations for the management of patients with EA. METHODS: MEDLINE, EMBASE and Cochrane databases were searched up to October 2015. The first part of the systematic literature review (SLR) involved a search for studies investigating the recognition and referral of EA...
2017: RMD Open
https://www.readbyqxmd.com/read/28155022/rituximab-in-anca-associated-vasculitis
#10
REVIEW
Romina I Hassan, Angelo L Gaffo
PURPOSE OF REVIEW: The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). RECENT FINDINGS: A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not...
February 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28151539/non-pharmacological-and-pharmacological-interventions-in-patients-with-early-arthritis-a-systematic-literature-review-informing-the-2016-update-of-eular-recommendations-for-the-management-of-early-arthritis
#11
Claire Immediato Daien, Charlotte Hua, Bernard Combe, Robert Landewe
OBJECTIVE: To perform a systematic literature review (SLR) on pharmacological and non-pharmacological treatments, in order to inform the European League Against Rheumatism (EULAR) recommendations for the management of early arthritis (EA). METHODS: The expert committee defined research questions concerning non-pharmacological interventions, patient information and education, non-steroidal anti-inflammatory drug, glucocorticoid (GC) and disease-modifying antirheumatic drugs (DMARDs) use, as well as on disease monitoring...
2017: RMD Open
https://www.readbyqxmd.com/read/28150104/assessment-of-six-cardiovascular-risk-calculators-in-mexican-mestizo-patients-with-rheumatoid-arthritis-according-to-the-eular-2015-2016-recommendations-for-cardiovascular-risk-management
#12
Dionicio A Galarza-Delgado, Jose R Azpiri-Lopez, Iris J Colunga-Pedraza, Jesus A Cardenas-de la Garza, Raymundo Vera-Pineda, Griselda Serna-Peña, Rosa I Arvizu-Rivera, Adrian Martinez-Moreno, Martin Wah-Suarez, Mario A Garza Elizondo
Variability of the 10-year cardiovascular (CV) risk predicted by the Framingham Risk Score (FRS) using lipids, FRS using body mass index (BMI), Reynolds Risk Score (RRS), QRISK2, Extended Risk Score-Rheumatoid Arthritis (ERS-RA), and algorithm developed by the American College of Cardiology and the American Heart Association in 2013 (ACC/AHA 2013) according to the European League Against Rheumatism (EULAR) 2015/2016 update of its evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis (RA) has not been evaluated in Mexican mestizo patients...
February 1, 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28149009/serum-lipid-alterations-in-early-rheumatoid-arthritis-patients-on-disease-modifying-anti-rheumatoid-therapy
#13
Sana Parveen, Rachel Jacob, Liza Rajasekhar, C Srinivasa, Iyyapu Krishna Mohan
Dyslipidaemia is a major CVD risk factor in the general population. Current evidence suggests that lipid metabolism is altered in RA due to inflammation, and that use of anti-inflammatory therapy may reverse some of these changes. The objective of our study is to compare the effect of treatment with DMARD on lipid fractions after 6 months of therapy. Forty patients who met the American College of Rheumatology, ACR/EULAR criteria for rheumatoid arthritis, with disease duration of less than 1 year and no prior treatment were included in the study...
March 2017: Indian Journal of Clinical Biochemistry: IJCB
https://www.readbyqxmd.com/read/28143836/periodontitis-in-early-and-chronic-rheumatoid-arthritis-a-prospective-follow-up-study-in-finnish-population
#14
Leena Äyräväinen, Marjatta Leirisalo-Repo, Antti Kuuliala, Kirsi Ahola, Riitta Koivuniemi, Jukka H Meurman, Anna Maria Heikkinen
OBJECTIVES: To investigate the association between rheumatoid arthritis (RA) and periodontitis with special emphasis on the role of antirheumatic drugs in periodontal health. DESIGN: Prospective follow-up study. Patients with early untreated RA and chronic active RA were examined at baseline and 16 months later. Controls were examined once. SETTINGS AND PARTICIPANTS: The study was conducted in Finland from September 2005 to May 2014 at the Helsinki University Hospital...
January 31, 2017: BMJ Open
https://www.readbyqxmd.com/read/28134078/diagnosis-and-treatment-of-rheumatoid-arthritis-in-the-emilia-romagna-region-a-prospective-population-based-study
#15
Olga Addimanda, Massimiliano Marino, Ilaria Farina, Marica Trevisani, Eugenio Arrigoni, Federica Lumetti, Filippo Crescentini, Paola Sambo, Alessandra Bezzi, Marco Bruschi, Daniele Santilli, Massimo Reta, Simona Bosi, Giovanni Delsante, Francesco Girelli, Luca Montaguti, Riccardo Meliconi, Marco Sebastiani, Clodoveo Ferri, Nazzarena Malavolta, Marcello Govoni, Susanna Trombetti, Rossana De Palma, Carlo Salvarani
OBJECTIVES: To perform a population-based study in rheumatoid arthritis (RA) patients, in order to evaluate the efficacy and safety of pharmacologic treatments. METHODS: 1087 patients with RA were enrolled; inclusion criteria were: newly diagnosed RA, already diagnosed RA with high disease activity (HDA) (DAS28≥4.2) starting biologic DMARDs (bDMARDs), already diagnosed RA with HDA continuing with conventional DMARDs (cDMARDs). The following data were collected: demographics, clinical and laboratory features, imaging and prescribed drugs...
January 27, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/28125360/monitoring-total-body-inflammation-and-damage-in-joints-and-entheses-the-first-follow-up-study-of-whole-body-magnetic-resonance-imaging-in-rheumatoid-arthritis
#16
M B Axelsen, I Eshed, M Østergaard, M L Hetland, J M Møller, D V Jensen, S B Krintel, M S Hansen, L Terslev, M Klarlund, R P Poggenborg, L Balding, S J Pedersen
OBJECTIVE: To investigate changes in whole-body magnetic resonance imaging (WBMRI) inflammatory and structural lesions in most joints and entheses in patients with rheumatoid arthritis (RA) treated with adalimumab. METHODS: WBMRI was obtained at weeks 0, 6, 16, and 52 in a 52 week follow-up study of 37 RA patients starting treatment with adalimumab. Readability and reliability of WBMRI were investigated for 76 peripheral joints, 23 discovertebral units, the sacroiliac joints, and 33 entheses...
January 26, 2017: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/28123778/factors-influencing-the-use-of-tocilizumab-as-monotherapy-in-patients-with-rheumatoid-arthritis-in-a-real-life-setting-results-at-1%C3%A2-year-of-the-act-solo-study
#17
René-Marc Flipo, Jean-Francis Maillefert, Pascal Chazerain, Isabelle Idier, Mathieu Coudert, Jacques Tebib
INTRODUCTION: Using a biologic disease-modifying antirheumatic drug (bDMARD) as monotherapy in clinical practice for patients with rheumatoid arthritis (RA) is common and recognised by health authorities although current guidelines recommend to combine them with conventional synthetic (cs)DMARDs. This study mainly aimed to search for real-life factors influencing the use of tocilizumab as MONO or in combination (COMBO). METHODS: In this non-interventional, prospective, national, multicentre study, data were collected every 3 months over a 12-month period in RA patients starting tocilizumab...
2017: RMD Open
https://www.readbyqxmd.com/read/28121204/efficacy-of-golimumab-for-preventing-large-joint-destruction-in-patients-with-rheumatoid-arthritis-as-determined-by-the-arashi-score
#18
Katsuaki Kanbe, Koei Oh, Junji Chiba, Yasuo Inoue, Masashi Taguchi, Akiko Yabuki
OBJECTIVES: To investigate the inhibitory effect of golimumab on large joint destruction in patients with rheumatoid arthritis. METHODS: We recruited 45 patients with rheumatoid arthritis and evaluated the radiographic severity of large joint destruction using the ARASHI (assessment of rheumatoid arthritis by scoring of large joint destruction and healing in radiographic imaging) score. We evaluated 450 large joints including the elbow, shoulder, hip, knee and ankle at baseline and 52 weeks after treatment with golimumab...
January 25, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28120818/pregnancy-and-menopause-in-patients-with-systemic-lupus-erythematosus-and-or-antiphospholipid-syndrome-practical-guide-from-eular
#19
Roberta Vagelli, Chiara Tani, Marta Mosca
Over the last few decades, in reproductive medicine have allowed an improvement in the management and outcome of pregnancy in connective tissue diseases (CTD), such as Systemic progress Lupus Erythematosus and Antiphospholipid Syndrome; however, pregnancy and other related issues represent a crucial moment for patients and their family and some unmet needs are still present. In routine clinical practise, health professionals involved in the care of SLE and/or APS patients need to consider many aspects of the reproductive life of patients, involving not only pregnancy and family planning but also fertility, contraception, cancer surveillance and menopause...
January 25, 2017: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/28107378/polymorphisms-in-stat4-ptpn2-psors1c1-and-traf3ip2-genes-are-associated-with-the-response-to-tnf-inhibitors-in-patients-with-rheumatoid-arthritis
#20
Paola Conigliaro, Cinzia Ciccacci, Cristina Politi, Paola Triggianese, Sara Rufini, Barbara Kroegler, Carlo Perricone, Andrea Latini, Giuseppe Novelli, Paola Borgiani, Roberto Perricone
OBJECTIVE: Rheumatoid Arthritis (RA) is a progressive autoimmune disease characterized by chronic joint inflammation and structural damage. Remission or at least low disease activity (LDA) represent potentially desirable goals of RA treatment. Single nucleotide polymorphisms (SNPs) in several genes might be useful for prediction of response to therapy. We aimed at exploring 4 SNPs in candidate genes (STAT4, PTPN2, PSORS1C1 and TRAF3IP2) in order to investigate their potential role in the response to therapy with tumor necrosis factor inhibitors (TNF-i) in RA patients...
2017: PloS One
keyword
keyword
85959
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"